A Versatile Vessel for Next-gen Therapeutics: Harvard’s ARMMs Technology to Be Commercialized by Vesigen Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Harvard University’s Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest. Through an exclusive license agreement with Harvard, Vesigen will develop